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Aims: Based on the hypothesis that first-line chemoradiation followed by chemotherapy was superior for primary
tumor and non-inferior for distant lesions compared to chemotherapy alone in synchronous unresectable distant
metastases rectal adenocarcinoma, this study was designed to assess the efficacy and safety of this strategy.
Materials and methods: Thirty two eligible patients received intensity modulated radiation therapy (45 Gy to the
pelvis and a concomitant 10 Gy boost to the gross tumor), along with concurrent weekly capecitabine and
oxaliplatin. Patients underwent radical surgery if all lesions were visually evaluated as resectable and received
chemotherapy for a total of 6 months, whether pre- or post-operatively (definitive therapy group). The remaining
patients received 6 months of consolidation chemotherapy followed by maintenance chemotherapy (non-definitive
therapy group).
Results: The toxicities were acceptable, with radiation-induced dermatitis around the anal verge being the most
common (18.8%). Fourteen patients underwent surgical resection of the rectal tumor, with 5 (35.7%) experiencing a
pathological complete response. Nine out of 14 received definitive treatment, defined as R0 resections of all visible
tumors. At a median follow-up of 12 months (range, 4–23 months), 2 cases were evaluated as local failure, and the
median overall survival (OS) and progression free survival (PFS) for all 32 patients were 17.5 and 12 months,
respectively. OS differed significantly in the definitive and non-definitive therapy groups (p=0.045), and PFS tended
to differ (p=0.274).
Conclusion: It was demonstrated that the strategy of first-line chemoradiation followed by chemotherapy was
effective and tolerable, especially for local control. OS and PFS were superior in patients who did than did not
undergo curative therapy.
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Synchronous distant metastases have been detected in
15%–25% of patients newly diagnosed with rectal cancer
[1,2]. Surgery remains the only potentially curative modal-
ity, with complete surgical resection of all visible tumors
resulting in a 5-year survival rate of 30%–40% [3-5]. How-
ever, approximately 80%–90% of newly diagnosed patients
have unresectable metastatic disease [2,6,7].
Systematic chemotherapy has been used to treat
patients with metastases from colorectal cancer. For ex-
ample, of 1014 initially unresectable patients with colorec-
tal liver disease treated with chemotherapy, with most
receiving oxaliplatin, 138 (12.5%), evaluated as “good
responders”, were able to undergo secondary hepatic re-
section, with a 5-year overall survival (OS) rate of 33% [5].
The intergroup N9741 trial found that the rate of curative
resection after chemotherapy was 3.3%, and the median
overall survival time for this group was 42.4 months [8].
To date, there is no consensus regarding the use of
radiotherapy in the treatment of synchronous metastases
from rectal cancer, although neoadjuvant chemoradia-
tion has shown significant benefits in patients with stage
II/III rectal cancer, including better local control and
sphincter preservation [9-11]. This prospective clinical
trial therefore assessed the efficacy and safety of first-
line chemoradiotherapy in patients with synchronous
metastases of rectal cancer; we also compared our




We enrolled patients aged 18 to 75 years with histologi-
cally confirmed, newly diagnosed, rectal adenocarcinoma,
concurrent with synchronous unresectable distant metas-
tases. The primary tumor in each patient was a locally
advanced mass (cT3-T4 and/or cN+), located within
12 cm from the anal verge. Each patient had significant
local symptoms, such as pain, bleeding or incomplete ob-
struction; a Karnofsky Performance Status ≥60; Adequate
bone marrow (leukocyte count >4,000/mL, platelet count
>100,000/mL), renal (creatinine clearance > 50 mL/min)
and hepatic (bilirubin ≤2 mg/mL) function. Patients were
excluded if they had previously received pelvic radiother-
apy or chemotherapy; had previous tumors other than
nonmelanoma skin cancer; or had ischemic heart disease,
inflammatory bowel disease, malabsorption syndrome,
peripheral neuropathy, or psychological disorders. Each
patient provided written informed consent.
Baseline evaluation
Pretreatment evaluation, performed within 2 weeks before
initiation of study treatment, included a complete history
and physical examination including a digital rectalexamination, complete blood count, platelet count, liver
and renal function tests, assays of gastrointestinal tumor
markers, colonoscopy with biopsy, computed tomography
(CT) of the chest and abdomen, and magnetic resonance
imaging (MRI) of the pelvis, with selected patients evalu-
ated by positron emission tomography-computed tomog-
raphy (PET-CT) scanning.
Intensity modulated radiation therapy (IMRT)
All patients were immobilized in the prone position using
a belly board and underwent a non-contrast-enhanced,
planning CT with 5-mm slices from the L3-L4 junction to
2 cm below the perineum. Imaging data were transferred
to the PINNACLE planning system (Philips Radiation On-
cology Systems, Milpitas, CA). The clinical target volume
1 (CTV1) included the gross tumor volume and the corre-
sponding mesorectum plus 2 cm cranio-caudally [12]. The
CTV2 included the CTV1 plus the entire mesorectum,
the entire pre-sacral space, the internal iliac nodes and the
high-risk anatomical and nodal sub-sites, based on the
distance of the tumor from the anal margin. The planning
target volume (PTV) was defined as the CTV with 10-
mm margins superiorly and inferiorly and 8-mm margins
in all other directions.the CTV plus 0.8 cm margin in all
directions. Organs at risk (OARs) were contoured as fol-
lows: 1) the small intestine was defined as all intestinal
loops below the sacral promontory (recto sigmoid junc-
tion excluded); 2) femoral heads were contoured from the
cranial extremity to the level of the lower margin of ischial
tuberosities; 3) the bladder was contoured entirely with no
distinction between the wall and its content [13]. The
IMRT plans were generated using the inverse planning
module of PINNACLE for a 6-MV liner accelerator, with
five to seven coplanar fields. The planned doses to the
PTV1 and PTV2 were 55 Gy and 45 Gy, in 25 fractions, 5
times per week (Monday through Friday) for 5 weeks. The
positioning and isocenter of each patient were verified on
electronic portal imaging device (EPID) films for the an-
terior and lateral gantry positions by visually comparing
the digitally reconstructed radiographs.
Concurrent chemotherapy
Patients received capecitabine (625 mg/m2 twice daily)
plus oxaliplatin (50 mg/m2 weekly) concurrent with pelvic
radiation throughout the entire course of radiotherapy.
Chemotherapy and surgery
Patients were evaluated after the completion of CRT and
every two months later. If all lesions were evaluated as re-
sectable by our weekly tumor board in six months,
patients would be planed to receive a radical surgery. The
sequence of primary and secondary tumors, the type of
surgery (lower anterior or abdominal–perineal resection)
and whether a temporary colostomy should be performed
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scheduled to receive a total of 6 months of chemotherapy,
whether pre- or post-operative, with Xelox (intravenous
oxaliplatin 130 mg/m2 on day 1 plus oral capecitabine
1000 mg/m2 twice daily on days 1–14 every three weeks).
For these patients who had no chance to receive a radical
surgery, it was recommended to receive 6 months’ Xelox,
followed by maintenance chemotherapy with capecitabine
alone. If tumor progressed, the chemotherapy regimen
would be changed to FOLFIRI regimen.
Patients at high risk of obstruction or significant
bleeding underwent palliative surgery to remove the pri-
mary tumor.
Evaluation of tumor response
Physical examinations and blood counts were performed
every week during chemoradiation. Hepatic, renal func-
tion tests, computed-tomography (CT) scans of thorax
and abdomen, magnetic Resonance Imaging (MRI) of
pelvis were assessed at baseline and repeated every
2 months. Tumor response was assessed according to
the RECIST criteria [14]. Complete response (CR) was
defined as complete disappearance of all clinically as-
sessable disease for at least 4 weeks, and partial response
as a decrease of at least 30% of the sum of the products
of the diameters of measurable lesions for at least
4 weeks. CT scans were done 4 weeks later to confirm a
response. Stable disease was defined as a decrease of less
than 30% or an increase of less than 20% of measurable
lesions, and progressive disease as an increase of at least
20% of measurable lesions or the appearance of new ma-
lignant lesion(s). All CT/MRI scans were subjected to
external review by at least two radiologists.
Evaluation of toxicity
Toxicity was evaluated according to the CTC-AE (Com-
mon Terminology Criteria for Adverse Events) 3.0 cri-
teria. Doses were adjusted or discontinued in patients
with grade 3 toxicity; in general, the sequence of dose
adjustment or discontinuation was oxaliplatin, capecita-
bine and radiotherapy, unless the adverse effect was
strongly associated with a particular agent.
Study design and endpoints
The primary end point of this trial was the objective re-
sponse rate (ORR, defined as CR+PR). This is a phase II
study of 32 patients to evaluate the treatment efficacy.
Based on published literatures, the objective response rate
is approximately 50% for patients treated with chemother-
apy alone [15]. We hypothesize that the ORR of first-line
CRT was 20% superior in primary tumor and no-inferior
in distant lesions to CT alone. With evaluation of all 32
patients, if more than 20 and 13 cases in primary and dis-
tant tumor were evaluated as objective response, we had85% power to reject the null hypothesis that first-line CRT
followed by CT couldn’t reach the ORR of 70% for pri-
mary tumor and 50% for distant lesions. Secondary end-
points included toxicity, PCR rate and survival rates.
Classified variables were described as frequencies; normal
distributional continuous data as means and standard
deviations; and non-normal distributional continuous data
as medians. Survival time was calculated from the begin-
ning of chemoradiotherapy (CRT) to the date of an event
or last follow-up. The Kaplan-Meier method was used to
estimate survival and PFS curves, and the log-rank test
was used to compare the curves [16].
Results
Demographic and clinical features
Between January 2010 and June 2011, 32 patients were
enrolled in this study (Table 1). There were 28 males
and 4 females, of median age 58.5 years (range, 35–
75 years). The median distance of the rectal mass from
the anal verge was 5 cm (range, 3–10 cm). Nineteen
patients were classified as T3 and 13 as T4; lymph node
involvement was detected in all patients, with 29 of N2
status. Liver metastases were the most common distant
lesions, observed in 28 patients; in addition, 26 patients
had more than 3 distant lesions and 12 showed involve-
ment of more than one distant organ.
Combined chemoradiotherapy
Twenty-nine patients received radiation doses of 55 Gy,
the other 3 received irradiation dose ranging from
46.2 Gy to 52.8 Gy. All patients completed concurrent
weekly capecitabine and at least 3 cycles of oxaliplatin
during the course of CRT.
Most of the adverse events during CRT were mild
(Table 2). No grade 4–5 toxicities were observed. The
most common grade 3 toxicity was radiation dermatitis
around the anal verge (18.8%), with 5 patients (15.6%)
having grade 3 gastrointestinal toxicity.
Tumor response to CRT
All patients were evaluated for tumor response at
2 months after the beginning of CRT, including
responses of the rectal mass and distant metastases. The
response rate of rectal masses was 68.75% (22/32), in-
cluding 4 patients with clinical complete response (cCR)
and 18 with clinical partial response (cPR), and 2
showed progressive disease (PD). The response rate of
distant lesions was 50% including 1 cCR and 15 cPR.
Progression was observed in two patients whose primary
tumor was also evaluated as PD.
Surgery
Nine patients underwent surgical resection of all visible
lesions and received definitive therapy. The other 5






















liver alone 16 50.0
lung alone 3 9.4
bone alone 1 3.1
liver and lung 10 31.3







Table 2 Toxicity during the course of chemoradiation
Grade 1 Grade 2 Grade 3
n % n % n %
Diarrhea 11 34.4 5 15.6 5 15.6
Hematologic 6 18.8 3 9.4 2 6.3
Fatigue 4 12.5 4 12.5 2 6.3
Radiation dermatitis 9 28.1 9 28.1 6 18.8
Neurosensory 1 3.1 1 3.1 0 0.0
Hand-foot syndrome 0 0 1 3.1 0 0.0
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(Table 3). The median interval between the completion of
CRT and primary tumor’s surgery was 11 weeks (range,
6–24 weeks), with 7 each undergoing APR and AR. YpT0
and ypN0 were found in 5 (35.7%) and 10 (71.4%)
patients, respectively, with 5 patients (35.7%) showing a
pathologic complete response (pCR). Down-staging of the
primary tumor occurred in 12 patients (85.7%).
Follow up
At a median follow-up of 12 months (range, 4–23 months),
5 patients required a decreased chemotherapy dose be-
cause of toxicities. Twenty patients experienced tumor
progression, including 20 with progression of distant
lesions and 2 with progression of local lesions, and 12
patients died of tumor progression. The median OS and
PFS of the 32 patients were 17.5 and 12 months (Figure 1).
When patients were divided into the 9 who received defini-
tive therapy and the other 23 who did not, there was a sig-
nificant between group difference in OS (p=0.045;
Figure 2), and a non-significant difference in PFS (p=0.274;
Figure 3).
Further analysis of the 9 patients who received definitive
therapy
The demographic and clinical features of two groups
who received definitive therapy or not are shown in
Table 4. No statistic difference was found in all factors
between two groups. These 9 patients underwent surgi-
cal resection of the primary tumor at a median 13 weeks
(range, 11–21 weeks) after CRT, with 5 undergoing APR
and 4 undergoing AR. Three patients experienced pCR
and downstaging was confirmed in 8 cases. One patient
showed disappearance of distant metastases after CRT,















Figure 1 Kaplan-Meier analysis of overall survival (OS) and progression free survival (PFS) of all 32 patients.
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completion of CRT.
At a median follow of 15 months (range, 8–21 months),
local-regional and distant recurrences were observed in 0
and 5 patients, respectively. One patient died of liver me-
tastases 8 months after CRT.Figure 2 Kaplan-Meier analysis of progression-free survival (PFS) in pDiscussion
In our study, the primary rectal tumor was treated with
combined CRT, whereas the distant lesions were treated
only with chemotherapy. This chemotherapy regimen, con-
sisting of oxaliplatin plus capecitabine, was expected to im-
prove the overall tumor response, especially for lesionsatients who did and did not receive definitive treatment.
Figure 3 Kaplan-Meier analysis of overall survival (OS) in patients who did and did not receive definitive treatment.
Table 4 Demographic and clinical characteristics in
different groups according to receiving definitive therapy
or not




Female 2 2 0.557*
Age
Median 57 59
Range 41-65 35-76 0.765$
Distance from anal verge
Median 5 5
Range 3-8 3-10 0.649$
Initial T stage
T3 6 13
T4 3 10 0.238#
Initial N stage
N1 0 3
N2 9 20 0.541*
Initial metastases number
<=3 2 1
>3 7 22 0.184*
Total 9 23
* Fisher exact test; # Chi-square test; $ Non-parameter Mann-Whitney rank-sum
test.
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tumors responded to treatment and that this was due
solely to weekly chemotherapy, similar to the response to
FOLFOX or FOLFIRI in patients with stage IV colorectal
cancer [17]. Nine of 32 patients (28.1%) received definitive
therapy after CRT and CT, a percentage similar to other
studies using FOLFOX [5,6]. Moreover, 30 of these 32
patients experienced progression-free local control after
CRT, better than the outcome from chemotherapy alone
[17]. Therefore, our preliminary results supported the hy-
pothesis that first-line CRT followed by chemotherapy was
superior for primary tumor and non-inferior for distant
lesions compared to chemotherapy alone.
Intensified CRT may significantly increase toxicities,
which would have a negative impact on subsequent CT.
To reduce toxicities, we therefore used the IMRT tech-
nique to decrease doses delivered to the surrounding
normal organs, including the bowel, bladder and femoral
head. For example, use of the IMRT decreased the vol-
ume of 45 Gy to the small bowel decreased by more
than 64% [18]. Moreover, a comparison of IMRT with
3DCRT in 10 patients found that IMRT had similar tar-
get coverage with reduced doses to the small bowel,
bladder, pelvic bones and femoral heads [15]. These find-
ings were supported by our results, showing toxicities
using IMRT were acceptable and most patients could be
treated according to the original CT schedule.
We found that 9 of our 32 patients received definitive
treatment, including the removal of all visible masses,
Zhu et al. Radiation Oncology 2013, 8:10 Page 7 of 7
http://www.ro-journal.com/content/8/1/10and that these patients had a longer PFS and OS. Re-
move of all visible tumors is critical. Further analysis,
however, showed that 5 of these 9 patients experienced
distant relapse during follow up. The high distant failure
rate was partly due to the initial tumor burden, with
most patients having more than 3 distant lesions at ini-
tial diagnosis. Total surgical resection after neoadjuvant
therapy has been based on the reduction or disappear-
ance of these lesions. However, pCR and cCR rates were
not identical, with consistencies of only 50% to 75%.
Therefore, recurrence in situ would occur in 40% to 74%
of patients whose liver metastases showed a cCR [19,20].
Furthermore, most relapses in our patients occurred
after the completion of 6 months of chemotherapy, simi-
lar to the results of previous trials [21,22]. Since residual
tumor cells may reproduce after the completion of
chemotherapy, maintenance chemotherapy may be es-
sential in increasing the disease-free interval in stage IV
patients, despite having undergone a “curative surgery”.
Conclusion
Our preliminary data showed that first-line CRT was ef-
fective and tolerable, especially for local control and may
be applicable to selected patients with synchronous me-
tastases of rectal cancer. A randomized controlled clin-
ical trial is warranted to compare CRT and CT in
patients with stage IV rectal cancer further.
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